Abstract 24P
Background
Non-invasive early diagnosis of cancer is a highly desirable goal in oncology. Plasma proteins have potential application in clinical practice as cancer biomarker. However, their profiling in presence of small tumors, entails technical and biological challenges. Cutting-edge technologies could overcome these limitations. In the present study, we describe preliminary data on the assessment of circulating proteins in early breast cancer (eBC) patients from the RENOVATE trial by employing two high-throughput proteomics approaches.
Methods
The RENOVATE trial (NCT04781062) enrolled women with suspect breast lesions ≤ 2 cm. They were asked to donate blood sample (detailed information in Ravera et al., BMJ, 2021). Plasma samples from 31 cancer, 29 benign and 20 healthy donors, matched by age, body mass index (BMI), menopausal and smoking status, were tested by aptamer-based proteomics arrays (SomaScan Somalogic®). Nearly 370 proteins were reassessed on the same biospecimens, leveraging an antibody-DNA linker technology assay (Oncology panel, Olink®). Variance analysis was performed using ANOVA. Statistical tests with a p-value < 0.01 were considered significant. Proteomics signatures were identified by a penalized linear model (glmnet R package). The two assays correlation was evaluated using Intra-class correlation (ICC).
Results
Out of 7596 proteins, 29 showed a significant differences across the 3 groups. The detected proteins are mainly involved in differentiation, migration, and cell death pathways. The two platforms shared 300 targets; 99% (n=296) passed the quality control step. The two used methodologies displayed moderately consistent results with 22% of probes (n=66) with an ICC index ≥ 0.5.
Conclusions
In the present study, we performed a broad analysis of human circulating proteins. We detected proteins associated with early BC related to pathways influencing cancer development. Data were validated by an orthogonal technology. Despite the potentiality in early diagnosis, the application of advanced methodologies is constrained by costs, and the majority of detected biomarkers have not yet been validated by standardized routine assays. We are currently working on the validation of our findings by implementing low-throughput and low-cost methods.
Editorial acknowledgement
Clinical trial identification
NCT04781062 study start: 2021-01-19.
Legal entity responsible for the study
IRCCS Ospedale Policlinico San Martino.
Funding
AIRC - Italian Foundation for Cancer Research.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
73P - Effect of combination therapy with atezolizumab plus metformin on peripheral immune cells from NSCLC patients
Presenter: Luisa Amato
Session: Cocktail & Poster Display session
Resources:
Abstract
74P - Obesity regulates tumor progression and sensitivity to checkpoint blockade through the diet-microbiota-immunity axis
Presenter: Lysanne Desharnais
Session: Cocktail & Poster Display session
Resources:
Abstract
75P - Possible significance of the proline at position 325 in the recognition of the MX35 epitope of the NaPi2b transporter by monoclonal antibodies
Presenter: Leisan Bulatova
Session: Cocktail & Poster Display session
Resources:
Abstract
76P - Circadian control of neutrophil extracellular trap formation temporally regulates metastatic lung cancer progression
Presenter: Simon Milette
Session: Cocktail & Poster Display session
Resources:
Abstract
78P - Daily rhythmic expression of pro-tumoral programs in NSCLC shape cancer immunity and therapy response
Presenter: Alba de Juan
Session: Cocktail & Poster Display session
Resources:
Abstract
79P - Tumor cell-released autophagosomes (TRAPs) remodel the breast tumor microenvironment by inducing the formation of inflammatory cancer-associated fibroblasts (CAFs)
Presenter: Chengdong Wu
Session: Cocktail & Poster Display session
Resources:
Abstract
80P - Tumor microenvironment (TME) defines prognosis of EGFR-mutant non-small cell lung cancer (NSCLC)
Presenter: Lodovica Zullo
Session: Cocktail & Poster Display session
Resources:
Abstract
81P - Single-cell spatial landscape of NSCLC reveals subtype specific immune features
Presenter: Mark Sorin
Session: Cocktail & Poster Display session
Resources:
Abstract
82P - Tumor cell-released autophagosomes (TRAPs) promote breast cancer lung metastasis by modulating neutrophil extracellular traps formation
Presenter: XIAOHE ZHOU
Session: Cocktail & Poster Display session
Resources:
Abstract
83P - Evaluation of serum macrophage inhibitory cytokine 1 as a diagnostic biomarker for pancreatic cancer: A systematic review and diagnostic accuracy meta-analysis
Presenter: Muhammed Elfaituri
Session: Cocktail & Poster Display session
Resources:
Abstract